Abstract Migraine is among the highest impact illnesses in the global population. Its negative ramifications are personal, social, economic and work related. Research on the development of new preventative migraine therapies has been idle for decades. The introduction, shortly, of an innovative pharmacological class useful for migraine prevention, namely monoclonal antibodies towards calcitonin gene-related peptide or its receptor, opens a new, immense therapeutic scenario. The necessity to manage the chronic and refractory forms of migraine must not take our attention away from the target of the pre-chronic forms. This is the most important target in every study. Indeed, by reducing the evolution towards chronic and consequently refractory chronic migraine, we will reduce complications caused by pharmacological abuse, the serious disability of these devastating chronic states, and the healthcare expenses needed to manage chronicity, abuse and consequent pathologies. We will, lastly, be able to rehabilitate these patients to achieve a quality working and social life, and facilitate their reintegration into daily normality.
Commentary
The introduction of monoclonal antibodies (mAbs) towards calcitonin gene-related peptide (CGRP) or its receptors (CGRPr) for migraine prevention arises from the visionary Lars Edvinsson who, during the 1980s, foresaw within experimental models the possible role of this peptide in migraine, and constantly followed the seminal evolution of this scientific theory over time [1] [2] [3] . Following this innovative research, many data have been collected, from the study of 'gepants' (molecules useful for acute migraine treatment that were not developed because of evidence of hepatotoxicity [2] ), to the work on the promising novel treatments targeting CGRP, for which there are great expectations in the scientific and lay world of headaches [1] .
The CGRP pathway in migraine is now being investigated in randomized controlled trials (RCTs) using mAbs targeting CGRP(r) for the prevention of migraine. Data from phase II and III studies (of erenumab, galcanezumab, fremanezumab, and eptinezumab) are consistent for safety and efficacy and are expected to lead towards pivotal approval [4, 5] . The paper by Yuan et al. reviews data from various RCTs that made this research path towards the development of a new pharmacological class robust [6] . This opens new scenarios for unmet needs in the management of migraine, but also poses a series of questions.
The rationale of this commentary does not concern the analysis of individual mAb studies for CGRP or CGRPr in migraine, but rather is a reflection on the future role of these drugs in a disease with such a large impact on the general population. Fourteen percent of the global population suffers from migraine [7] , and we now have to imagine how to proceed in the dissemination of these new drugs. Excluding the prophylaxis of the episodic form of migraine, we will have to postpone for ethical and pharmacoeconomic reasons the choice to treat with CGRP(r) mAbs the medium frequency migraine subpopulation (4-5 migraine days per month) (Fig. 1) . Unfortunately, the tight application of existing guideline-recommended drugs could make this choice difficult. We must instead focus attention towards the highly disabling and costly forms; otherwise we would hypothesize treating almost 1 billion people with migraine. However, only 2% of the world's population suffers from chronic migraine [8] (with or without pharmacological abuse of acute drugs: analgesics, non-steroidal anti-inflammatory drugs, triptans, opioids, ergot derivatives, barbiturates, caffeine, etc. and their various combinations), and this chronic form is the current true challenge in headache management [9, 10] (Fig. 1) . We should attempt to prevent the chronicization of these patients, who constitute the core group with personal-social-working burden [11, 12] , and who fluctuate in a pre-chronic phase with high-frequency migraine crisis, but who are not yet chronic (Fig. 1) . Only in this way will we reduce the huge number of chronic migraine patients, who stray towards medication overuse headache (MOH) and are at risk of refractoriness. And only in this way will we reduce the cascade of multi-systemic pathologies (gastrointestinal, renal, cardiovascular, cerebral, psychiatric, etc.) originating from acute drug abuse, which are often not recognized or directly correlated with it. This is a top priority, because we know that the rehabilitation procedures for chronic migraine complicated by MOH present with relapse in 50% of patients within the first 12 months [10] . Another priority area of intervention is refractory migraine, as clinically defined by the European Headache Federation [13] . Refractory migraine is very hard to treat and has been the target for a number of ineffective invasive techniques [14] . These priority areas could represent immediate targets for the application of the new CGRP mAbs.
In addition to consideration of the sustainability of biologic therapies that will probably have a high cost, the need for close future pharmacovigilance activity or the design of specific ad hoc studies should also be highlighted. Since CGRP is ubiquitous and migraine shows comorbidity with many cardio-cerebrovascular pathologies, it is important to monitor for any possible risk of interference [15] . CGRP(r) block is involved not only in the treatment of migraine pain but also in somatic, visceral, neuropathic and inflammatory pain [16] .
Without a doubt, this new pharmacological class will be strategic in the management of migraine, one of the most high-impact and widespread non-communicable diseases, and we must also be aware that RCTs are sometimes far from real-world evidence [17] . One last but significant barrier might be the pricing of these molecules: will they be accessible to every patient with the abovementioned priorities or will there be a reimbursement revolving around health insurance or social health? We are strongly confident that, with the necessary prescriptive filter of certified expert physicians, the future of our migraine patients will soon be much brighter than it is today.
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Conflicts of interest Paolo Martelletti has received fees for participation on advisory boards from Teva, Allergan, Amgen, Novartis, and Electrocore; educational grants from Allergan, ACRAF, and Pfizer; royalties from Springer; research grants from Elytra Pharma, and Sanofi; travel reimbursement from EFIC, EHF and Springer Nature; and an editorial grant from Springer Nature. Fig. 1 Proposed rational application of CGRP(r) monoclonal antibodies in the migraine spectrum to prevent chronicity. Blue: no preventative treatment; Yellow: low priority for preventative CGRP(r) treatment; Orange: medium to high priority for preventative CGRP(r) treatment; Green: very high priority for preventative CGRP(r) treatment. CGRP calcitonin gene-related peptide, mAb monoclonal antibody
